PHENOBARB phenobarbital 30mg tablet bottle

দেশ: অস্ট্রেলিয়া

ভাষা: ইংরেজি

সূত্র: Department of Health (Therapeutic Goods Administration)

সক্রিয় উপাদান:

phenobarbital, Quantity: 30 mg

থেকে পাওয়া:

Arrotex Pharmaceuticals Pty Ltd

ফার্মাসিউটিকাল ফর্ম:

Tablet, uncoated

রচনা:

Excipient Ingredients: lactose monohydrate; magnesium stearate; Acacia; wheat starch

প্রশাসন রুট:

Oral

প্যাকেজ ইউনিট:

200 tablets

প্রেসক্রিপশন টাইপ:

(S4) Prescription Only Medicine

থেরাপিউটিক ইঙ্গিত:

Epilepsy; sedation

পণ্য সারাংশ:

Visual Identification: A white, round biconvex tablet with a scoreline on one side and plain on the other side.; Container Type: Bottle; Container Material: Glass Type III Coloured; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

অনুমোদন অবস্থা:

Registered

অনুমোদন তারিখ:

1991-10-14

তথ্য লিফলেট

PHENOBARB TABLETS
Phenobarbital (phenobarbitone) 30 mg
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about the Phenobarb
tablets.
It does not contain all the available
information. It does not take the place
of talking to your doctor or
pharmacist.
All medicines have risks and benefits.
Your doctor has weighed the risks of
you taking Phenobarb tablets against
the benefits they expect it will have
for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT PHENOBARB TABLETS
ARE USED FOR
Phenobarb tablets contain the active
ingredient
Phenobarbital (phenobarbitone),
which belongs to a group of
medicines called barbiturates.
Barbiturates act by inducing sleep
and stopping convulsions.
Phenobarb tablets are used for:
•
epileptic fits
•
sedation.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY PHENOBARB
TABLETS HAVE BEEN PRESCRIBED FOR
YOU.
Your doctor may have prescribed it
for another purpose.
It is available only with a doctor's
prescription.
The use of barbiturates may lead to
dependence on the medicine.
BEFORE YOU TAKE IT
_When you must not take it _
Do not take Phenobarb tablets if you
are allergic to:
•
Phenobarbital (phenobarbitone)
•
any other ingredients listed at the
end of this leaflet.
Some of the symptoms of an allergic
reaction may include red, itchy skin
rashes, difficulty breathing, hayfever,
swelling of the face or throat or
faintness.
PHENOBARB TABLETS SHOULD NOT BE
USED IF YOU HAVE OR HAVE HAD ANY
OF THE FOLLOWING MEDICAL
CONDITIONS:
•
porphyria, a rare blood pigment
disorder
•
anaemia, a disease of the blood
with reduced number of red blood
cells
•
uncontrolled severe asthma
•
uncontrolled diabetes mellitus or
sugar diabetes
•
alcoholism or drug dependence
•
liver or kidney problems
•
severe depression or suicidal
tendencies
•
or long term pain.
PHENOBARB TABLETS SHOULD NOT BE
GIVEN TO UNUSUALLY OVERACTIVE
CHILDREN.

পণ্য বৈশিষ্ট্য

1
AUSTRALIAN PRODUCT INFORMATION – PHENOBARB
(PHENOBARBITAL (PHENOBARBITONE)) TABLETS
1
NAME OF THE MEDICINE
Phenobarbital (phenobarbitone).
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
PHENOBARB tablets contain phenobarbital (phenobarbitone) 30 mg.
Excipients with known effect: gluten and lactose monohydrate.
For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS.
3
PHARMACEUTICAL FORM
PHENOBARB tablets are white, round uncoated biconvex tablets with a
scoreline on one side and
plain on the other side.
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Epilepsy, sedation.
4.2
D
OSE AND METHOD OF ADMINISTRATION
ANTICONVULSANT
_Adults _
60 to 240 mg per day in 2 to 3 divided doses.
_Paediatric _
1 to 6 mg per kg per day in 2 to 3 divided doses.
Phenobarbital (phenobarbitone) may be given as a single daily dose as
it has a long half-life. Doses
must be individualised.
2
SEDATIVE_ _
_Adults _
30 to 120 mg per day in 2 to 3 divided doses.
_Paediatric _
1 to 2 mg per kg 2 to 3 times a day.
Alternatively phenobarbital (phenobarbitone) may be given as a single
daily dose.
Geriatric and debilitated patients may exhibit excitement, confusion
or depression with usual
therapeutic doses. Lower doses are recommended.
4.3
C
ONTRAINDICATIONS
Phenobarbital (phenobarbitone) is not recommended in the presence of
the following conditions:
•
a history of porphyria, either acute intermittent or variegata
•
hypersensitivity to barbiturates or the excipients in the tablets
•
severe anaemia (if it is due to folate deficiency)
•
severe asthma (if uncontrolled)
•
diabetes mellitus (if uncontrolled)
•
a history of drug abuse or dependence
•
severe hepatic or renal impairment
•
hyperkinetic children
•
severe depression or suicidal tendencies
•
acute or chronic pain (paradoxical excitement may result or other
symptoms may be
masked).
4.4
S
PECIAL WARNINGS AND PRECAUTIONS FOR USE
WOMEN OF CHILDBEARING POTENTIAL
Phenobarbital may cause fetal harm when administered to a pregnant
woman. Prenatal exposure to
phen